BioPartner UK

To enhance our expertise in the Cytokine Release Syndrome space we have appointed Dr Adrian Kilcoyne to our Scientific Advisory Board. Dr Kilcoyne bring over 20 years of clinical expertise with strategic drug development leadership, focusing on innovative therapies that address unmet medical needs in oncology and immunology and, in particular, brings deep knowledge of haematological malignancies, T-cell therapies and Cytokine Release Syndrome. Adrian’s wealth of experience will provide further support to our established team of experts as we progress POLB 001 through the TOPICAL trial with the ultimate aim of transforming cancer care for patients and healthcare systems. Learn more about Dr Kilcoyne’s experience and read the full announcement here: londonstockexchange.com/news-article/P… #POLB #SAB #ScientificAdvisory #BoardMember #AIM #Cancer #Oncology #ScientificExpert

And that was the 2025 #BionowAwards! Thank you to all our nominees, attendees and sponsors for making the evening truly special. Now head over to our event summary to check out the full list of award winners! bionow.co.uk/news/honouring… #LifeSciences #Networking #CelebratingSuccess

Develop your leadership and management skills with our 17 free online modules. They share the latest leadership tools to enable you to reflect on and practise new approaches. Login or register on NIHR Learn to find out more: learn.nihr.ac.uk/course/view.ph…

The @US_FDA has published a paper on a plausible mechanism pathway, a #regulatory framework to accelerate approval of bespoke, #patient-specific #therapies when traditional trials are not feasible. - For more information on this guidance, get in touch: scendea.com/contact

The @BioPartner News Roundup is out, featuring the #latestnews from our members, @Stablepharma1 and @_REPROCELL. We want to shout out our event partner @MedTechWorld. Catch the latest on our website – https:// lnkd.in/e6KUE5Zz #Lifesciences #NewsUpdate

The @US_FDA has published a guidance titled, “Scientific Considerations in Demonstrating #Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies (CES)”. - #guidanceupdate #scientificconsiderations #USregulatorysupport

Video clips & a post-event update from CEO Jeremy Skillington at this weeks' EBD Group's BIO-Europe in Vienna! The team were delighted to join so many industry colleagues to explore the future of biotech and pharma. A big thank you to everyone who took the time to connect with our team. We look forward to continuing the momentum and driving meaningful outcomes in the life sciences. #POLB #BIOEUROPE #Vienna #Conference #Pharma #Biotech

What an incredible week at #BIOEurope! A huge thank you to everyone who stopped by the #UKPavilion, your energy and our conversations made it a truly productive outing. BioPartner UK is proud to have showcased the best of #UKLifesciences with our amazing #UKDelegation. 🇬🇧

The #BionowAwards are NOW OPEN for applications until 16 JAN! 🏆 Whether you want to nominate a stellar colleague, celebrate an investment win or showcase that amazing project, ALL are welcome to make a submission. More info: bionow.glueup.com/event/2025-bio… #CelebratingSuccess

This week is RSV Awareness Week and at hVIVO, we’re proud to be at the forefront of innovation in RSV research and development. Respiratory Syncytial Virus (RSV) continues to pose a significant global health challenge, particularly for infants, older adults, and immunocompromised individuals. At hVIVO, we provide comprehensive, end-to-end support for the development and evaluation of RSV vaccines and antiviral therapeutics through our world-leading controlled human infection models and specialist laboratory services. Let’s work together to advance RSV science and protect vulnerable populations. Learn more about our dedicated RSV human challenge trial services by clicking on the link below or reach out directly on bd@hvivo.com: hvivo.com/human-challeng… #HVO #RSVWeek #RSV #ClinicalTrials #Vaccines #Antivirals #hLAB

Our CEO provides an overview on the clear plan to deliver shareholder returns through Poolbeg’s strategic & financial highlights. 🔹Our partnering focused model of cost-effective trials have been designed to produce high-quality human data and accelerate partnering discussions on our pipeline. 🔹We have a proven team with expertise in trial execution and deal-making. 🔹Well capitalised with a cash runway into 2027 supporting the delivery of multiple key clinical milestones. We have multiple potential value catalysts ahead, check out POLB 001’s here: poolbegpharma.com/pipeline/polb-… #POLB #Strategy #Partnering #AIM #London #CashBalance

☕🍪 Get ready for Biscuits & Brew! 🍪☕ Join @BioPartner UK for an informal networking break over a hot brew and some biscuits! Let's chat all things #BIOEurope2025, #Vienna, #UKDelegation, and more. Free to Attend, Register Here: lnkd.in/emZs7JRN #Biotech #Pharma

📸Relive the highlights of #BIOSPAIN2025! From groundbreaking biotech innovations to record-breaking connections, see how the international biotech community came together in Barcelona. ➡️Access the gallery: asebio.com/en/news-events…

Discover next generation therapies at the #CellandGeneTherapyInternational conference in #Berlin. Get 15% discount with BioPartner UK: lnkd.in/eyMEAzhM #Events2025 #Lifesciences #CellandGeneTherapy

The @US_FDA has introduced a pilot program to expedite the review of #ANDAs submitted by companies that conduct #bioequivalence testing and manufacture generic drug products domestically. - To discuss this guidance, get in touch: scendea.com/contact - #drugdevelopment

Our Principal Scientist, Liam Tremble, discusses our upcoming POLB 001 first-in-patient phase 2a trial. ✅Trial to be conducted by Accelerating Clinical Trials 🔬 Dr Emma Searle, Consultant Haematologist will be running at the Christie Foundation Trust 👉Number of other leading UK specialist cancer centres will participate 🎯Supply of approved bispecifc antibody secured at no cost to Poolbeg If you missed this announcement, catch up here: polaris.brighterir.com/public/poolbeg… #POLB #Phase2 #ClinicalTrials #UKTrials #Pharma #CRS #Bispecifics

Reminder 💡Our Chief Executive Officer Jeremy Skillington will be participating in a panel discussion at the Optimum 17th Annual Healthcare Investor Conference on Thursday 9 October. 📍The King’s Fund, London ⌚14:15 🗣️ Panel: Thriving in the tough times: scaling smart and staying strong Jeremy will take to the stage alongside Nicole Mather of IBM Consultingand Nick Keher, CFO at Oxford Nanopore. The session will be chaired by Kristin-Anne Rutter, Executive Director at Cambridge University Health Partners. Register to attend: #register" target="_blank" rel="nofollow noopener">optimumcomms.com/irconference20… #POLB #Conference #Investors #Healthcare #LifeScience #Pharma #London #Optimum

As proud supporter of the 2025 Cell and Gene Meeting on the Mesa, we’re gearing up for an electrifying event with leaders in #cellandgenetherapy to chart the sector's future. Get 10% discount with @BioPartner: #event:5270" target="_blank" rel="nofollow noopener">events.biopartner.co.uk/events_framed.… #CGMesa25 #Events2025 #Lifesciences

Check out our new website where you can navigate across the hVIVO Group services, including the integration of Venn Life Sciences, Cryostore and CRS service offering, highlighting our end-to-end clinical development services to a diverse and expanding client base. Our fully integrated drug development solutions from preclinical stages through to Phase III trials, alongside patient recruitment via @flucamp and CRS-Subjects . Additionally, our five clinical sites in the UK and EU support Phase I, Phase II and III trials, ensuring a seamless and efficient pathway from discovery to late-stage development. Check it out by clicking on the link below: hvivo.com #HVO #HCT #PreClinical #Phase2 #ScientificResearch #CRO

Tune in Deep Tech Digest Base to Base Biotech podcast with Jim Cornall who speaks to Chief Executive Officer Jeremy Skillington, PhD on Poolbeg Pharma’s exciting pipeline. 👉Company overview & history ✅POLB 001 addressing cancer immunotherapy-induced CRS 🔍About Cytokine Release Syndrome 🔬Upcoming Phase 2a trial 🚀Developing an oral, patient-friendly obesity treatment 🧑‍🔬Upcoming Proof of Concept Trial Listen here from 37:26: deeptechdigest.com/biotech/base-t… #POLB #Podcast #Biotech #CRS #Oncology #GLP1 #Pharma